The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...
The treatment combination was previously approved in BRCA2m-positive patients with metastatic castrate-resistant prostate cancer.
On December 12, 2025, the US Food and Drug Administration approved Johnson & Johnson subsidiary Janssen Biotech’s Akeega (niraparib and abiraterone acetate with prednisone for adults with deleterious ...
Abstract: Recombination of excess charge carriers in semiconductors occurring in emitter layers or at the interface to dielectric layers is typically assessed via injection-dependent lifetime ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback